JP7168558B2 - Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 - Google Patents

Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 Download PDF

Info

Publication number
JP7168558B2
JP7168558B2 JP2019518374A JP2019518374A JP7168558B2 JP 7168558 B2 JP7168558 B2 JP 7168558B2 JP 2019518374 A JP2019518374 A JP 2019518374A JP 2019518374 A JP2019518374 A JP 2019518374A JP 7168558 B2 JP7168558 B2 JP 7168558B2
Authority
JP
Japan
Prior art keywords
seq
strains
aspects
composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517828A5 (enExample
JP2019517828A (ja
Inventor
シュナイダー，ジェシカ
キム，ユン－ギ
オーレ，ベルナト
レディー，シルパ
ノーマン，ジェイソン
パタロヨ，フアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of JP2019517828A publication Critical patent/JP2019517828A/ja
Publication of JP2019517828A5 publication Critical patent/JP2019517828A5/ja
Priority to JP2022172637A priority Critical patent/JP7483828B2/ja
Application granted granted Critical
Publication of JP7168558B2 publication Critical patent/JP7168558B2/ja
Priority to JP2024074166A priority patent/JP2024109615A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019518374A 2016-06-14 2017-06-14 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 Active JP7168558B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022172637A JP7483828B2 (ja) 2016-06-14 2022-10-27 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
JP2024074166A JP2024109615A (ja) 2016-06-14 2024-05-01 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349914P 2016-06-14 2016-06-14
US62/349,914 2016-06-14
PCT/US2017/037498 WO2017218680A1 (en) 2016-06-14 2017-06-14 Treatment of clostridium difficile infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022172637A Division JP7483828B2 (ja) 2016-06-14 2022-10-27 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Publications (3)

Publication Number Publication Date
JP2019517828A JP2019517828A (ja) 2019-06-27
JP2019517828A5 JP2019517828A5 (enExample) 2020-07-27
JP7168558B2 true JP7168558B2 (ja) 2022-11-09

Family

ID=60664224

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019518374A Active JP7168558B2 (ja) 2016-06-14 2017-06-14 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
JP2022172637A Active JP7483828B2 (ja) 2016-06-14 2022-10-27 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
JP2024074166A Pending JP2024109615A (ja) 2016-06-14 2024-05-01 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022172637A Active JP7483828B2 (ja) 2016-06-14 2022-10-27 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
JP2024074166A Pending JP2024109615A (ja) 2016-06-14 2024-05-01 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Country Status (13)

Country Link
US (1) US12390498B2 (enExample)
EP (2) EP4282489A3 (enExample)
JP (3) JP7168558B2 (enExample)
KR (4) KR20250140643A (enExample)
CN (1) CN109562133A (enExample)
AU (2) AU2017285211B2 (enExample)
CA (2) CA3027917C (enExample)
DK (1) DK3468573T5 (enExample)
ES (1) ES2960053T3 (enExample)
FI (1) FI3468573T3 (enExample)
MX (2) MX2018015522A (enExample)
PT (1) PT3468573T (enExample)
WO (1) WO2017218680A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502391A (ja) * 2017-11-09 2021-01-28 ヴェダンタ バイオサイエンシーズ インコーポレーテッドＶｅｄａｎｔａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． アレルギーの処置のための組成物および方法

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3468573T (pt) 2016-06-14 2023-10-16 Vedanta Biosciences Inc Tratamento de uma infeção por clostridium difficile
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
EP4410954A3 (en) 2017-12-11 2025-01-15 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
WO2019191694A1 (en) * 2018-03-29 2019-10-03 Seres Therapeutics, Inc. Compositions and methods for treating inflammatory bowel diseases
JP2021527639A (ja) * 2018-06-19 2021-10-14 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 生物療法製品を含む剤形
US12161680B2 (en) * 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
IL265735A (en) 2019-03-31 2019-05-30 Biomica A microbial consortium and its uses
CN114258299A (zh) * 2019-07-17 2022-03-29 犹他大学研究基金会 梭菌纲聚生体组合物以及治疗肥胖症、代谢综合征和肠易激疾病的方法
GB201911728D0 (en) * 2019-08-15 2019-10-02 Genome Res Ltd Bacterial composistions for the treatment of disease
EP3858363A1 (en) 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
CN115867146B (zh) * 2020-02-07 2025-01-17 国际N&H丹麦有限公司 用于动物健康的饲料组合物
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
WO2022039561A1 (ko) * 2020-08-21 2022-02-24 서울대학교산학협력단 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물
KR102296288B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN117241809A (zh) 2021-01-21 2023-12-15 韦丹塔生物科学股份有限公司 用于治疗肝性脑病的组合物和方法
WO2022178292A1 (en) * 2021-02-18 2022-08-25 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
EP4341382A4 (en) * 2021-05-10 2025-04-30 Microba Ip Pty Ltd COMPOSITIONS AND METHODS FOR TREATING DISEASES
WO2023014048A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 비피도박테리움 속 균주 또는 페디오코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331483B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351147B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014054A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351146B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331484B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 마실리엔시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351145B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351148B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 펜토사세우스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331486B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331485B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102792000B1 (ko) * 2021-10-21 2025-04-08 경북대학교 산학협력단 신규한 락토바실러스 루테리 psc102 균주 및 이의 용도
KR102337995B1 (ko) * 2021-11-10 2021-12-14 주식회사 바이오뱅크힐링 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337998B1 (ko) * 2021-11-03 2021-12-14 주식회사 바이오뱅크힐링 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023075458A1 (ko) * 2021-10-27 2023-05-04 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102365420B1 (ko) * 2022-01-04 2022-02-23 주식회사 바이오뱅크힐링 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102444328B1 (ko) * 2022-03-11 2022-09-19 주식회사 바이오뱅크힐링 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
JPWO2023176951A1 (enExample) 2022-03-18 2023-09-21
KR102626400B1 (ko) * 2022-08-31 2024-01-19 주식회사 바이오뱅크힐링 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102628942B1 (ko) * 2023-08-08 2024-01-26 주식회사 바이오뱅크힐링 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
WO2025033636A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620185B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102620186B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
WO2025033635A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2025076184A1 (en) 2023-10-03 2025-04-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2025093777A1 (en) 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP2016509002A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205A (en) 1845-09-23 Spark-arrester
US132A (en) 1837-02-25 Improvement in propelling machinery by magnetism and electro-magnetism
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
KR101260533B1 (ko) 2005-03-03 2013-05-06 가부시키가이샤 메이지 면역기능 조정제
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
FI4032586T3 (fi) 2010-02-01 2025-11-25 Ferring Microbiome Inc Bakteeriterapia clostridium difficile -koliittiin
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012098358A1 (en) 2011-01-20 2012-07-26 Biopharma Technology Ltd Freeze drying method
WO2012162335A2 (en) 2011-05-23 2012-11-29 Washington State University Research Foundation Use of photosynthetic pigment stabilizing agents to regulate ripening and quality in fruits and vegetables
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
JP6201982B2 (ja) 2012-03-30 2017-09-27 味の素株式会社 糖尿病誘起細菌
EP3686284A1 (en) 2012-05-18 2020-07-29 Genome Research Limited Methods and groups
CN102743420A (zh) 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
WO2014029578A1 (en) 2012-08-24 2014-02-27 Haldor Topsøe A/S Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
WO2015051323A1 (en) 2013-10-03 2015-04-09 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MX387331B (es) 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.
WO2015164555A1 (en) 2014-04-23 2015-10-29 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
WO2015179437A1 (en) 2014-05-19 2015-11-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
DK3223835T3 (en) 2014-11-25 2025-02-17 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
CN107949391B (zh) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
KR20180010237A (ko) 2015-05-21 2018-01-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 건강 증진을 위한 박테리아 집단
WO2016201053A1 (en) 2015-06-09 2016-12-15 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN108135945A (zh) 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
WO2017008026A1 (en) 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis
US20200390830A1 (en) 2015-08-24 2020-12-17 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
BR112018008358A2 (pt) 2015-10-26 2019-04-24 Crestovo Holdings Llc ?composições e métodos para terapia relacionada à microbiota fecal?
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP4233884A3 (en) 2015-11-24 2023-10-04 Seres Therapeutics, Inc. Designed bacterial compositions
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
PT3468573T (pt) 2016-06-14 2023-10-16 Vedanta Biosciences Inc Tratamento de uma infeção por clostridium difficile
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
CN109562147B (zh) 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
WO2018080477A1 (en) 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols
US20210196766A1 (en) 2018-05-24 2021-07-01 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
US12161680B2 (en) 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
CN117241809A (zh) 2021-01-21 2023-12-15 韦丹塔生物科学股份有限公司 用于治疗肝性脑病的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2016509002A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cuicui Xiao, et al., Frontiers in Microbiology, July 2016, Volume 7 Article 1145, July 22, 2016
Narushima S. et al.，Gut Microbes，2014年，Vol. 5, Issue 3，p. 333-339

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502391A (ja) * 2017-11-09 2021-01-28 ヴェダンタ バイオサイエンシーズ インコーポレーテッドＶｅｄａｎｔａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． アレルギーの処置のための組成物および方法
JP7293220B2 (ja) 2017-11-09 2023-06-19 ヴェダンタ バイオサイエンシーズ インコーポレーテッド アレルギーの処置のための組成物および方法
JP2023121755A (ja) * 2017-11-09 2023-08-31 ヴェダンタ バイオサイエンシーズ インコーポレーテッド アレルギーの処置のための組成物および方法

Also Published As

Publication number Publication date
FI3468573T3 (fi) 2023-10-02
US12390498B2 (en) 2025-08-19
JP2023017845A (ja) 2023-02-07
DK3468573T5 (da) 2024-09-09
ES2960053T3 (es) 2024-02-29
AU2024216443A1 (en) 2024-09-19
EP4282489A2 (en) 2023-11-29
KR102554351B1 (ko) 2023-07-13
US20240123000A1 (en) 2024-04-18
KR20190030687A (ko) 2019-03-22
CA3226196A1 (en) 2017-12-21
EP4282489A3 (en) 2024-01-10
JP2024109615A (ja) 2024-08-14
AU2017285211B2 (en) 2024-06-27
JP7483828B2 (ja) 2024-05-15
DK3468573T3 (da) 2023-10-16
MX2023003461A (es) 2023-04-19
KR102862927B1 (ko) 2025-09-23
CN109562133A (zh) 2019-04-02
KR20230107416A (ko) 2023-07-14
AU2017285211A1 (en) 2019-01-24
CA3027917C (en) 2024-02-20
CA3027917A1 (en) 2017-12-21
PT3468573T (pt) 2023-10-16
EP3468573B1 (en) 2023-08-09
MX2018015522A (es) 2019-07-12
EP3468573A1 (en) 2019-04-17
JP2019517828A (ja) 2019-06-27
KR20250140643A (ko) 2025-09-25
KR102658297B1 (ko) 2024-04-18
EP3468573A4 (en) 2020-03-04
KR20240055124A (ko) 2024-04-26
WO2017218680A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7483828B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
US11701396B2 (en) Treatment of Clostridium difficile infection
US20250009811A1 (en) Compositions and methods for suppressing pathogenic organisms
WO2020008149A1 (fr) Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin
WO2021030198A1 (en) Compositions and methods for suppressing pathogenic organisms
Zhang et al. Safety evaluation of Lactobacillus paracasei subsp. paracasei LC-01, a probiotic bacterium
HK40104391A (en) Treatment of clostridium difficile infection
HK40114606A (en) Compositions and methods for suppressing pathogenic organisms
HK40007703B (en) Treatment of clostridium difficile infection
HK40007703A (en) Treatment of clostridium difficile infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221027

R150 Certificate of patent or registration of utility model

Ref document number: 7168558

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250